Literature DB >> 17670894

Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications.

Maya Shvartsman1, Raghavendra Kikkeri, Abraham Shanzer, Z Ioav Cabantchik.   

Abstract

Non-transferrin-bound iron, commonly found in the plasma of iron-overloaded individuals, permeates into cells via pathways independent of the transferrin receptor. This may lead to excessive cellular accumulation of labile iron followed by oxidative damage and eventually organ failure. Mitochondria are the principal destination of iron in cells and a primary site of prooxidant generation, yet their mode of acquisition of iron is poorly understood. Using fluorescent probes sensitive to iron or to reactive oxygen species, targeted to cytosol and/or to mitochondria, we traced the ingress of labile iron into these compartments by fluorescence microscopy and quantitative fluorimetry. We observed that 1) penetration of non-transferrin-bound iron into the cytosol and subsequently into mitochondria occurs with barely detectable delay and 2) loading of the cytosol with high-affinity iron-binding chelators does not abrogate iron uptake into mitochondria. Therefore, a fraction of non-transferrin-bound iron acquired by cells reaches the mitochondria in a nonlabile form. The physiological role of occluded iron transfer might be to confer cells with a "safe and efficient cytosolic iron corridor" to mitochondria. However, such a mechanism might be deleterious in iron-overload conditions, because it could lead to surplus accumulation of iron in these critical organelles.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17670894     DOI: 10.1152/ajpcell.00054.2007

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  24 in total

1.  Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.

Authors:  Emanuela Messa; Sonia Carturan; Chiara Maffè; Marisa Pautasso; Enrico Bracco; Antonella Roetto; Francesca Messa; Francesca Arruga; Ilaria Defilippi; Valentina Rosso; Chiara Zanone; Antonia Rotolo; Elisabetta Greco; Rosa M Pellegrino; Daniele Alberti; Giuseppe Saglio; Daniela Cilloni
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

Review 2.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

3.  Iron Supply via NCOA4-Mediated Ferritin Degradation Maintains Mitochondrial Functions.

Authors:  Motoki Fujimaki; Norihiko Furuya; Shinji Saiki; Taku Amo; Yoko Imamichi; Nobutaka Hattori
Journal:  Mol Cell Biol       Date:  2019-06-27       Impact factor: 4.272

4.  Modeling Secondary Iron Overload Cardiomyopathy with Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  June-Wha Rhee; Hyoju Yi; Dilip Thomas; Chi Keung Lam; Nadjet Belbachir; Lei Tian; Xulei Qin; Jessica Malisa; Edward Lau; David T Paik; Youngkyun Kim; Beatrice SeungHye Choi; Nazish Sayed; Karim Sallam; Ronglih Liao; Joseph C Wu
Journal:  Cell Rep       Date:  2020-07-14       Impact factor: 9.423

5.  Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

Authors:  David Devos; Caroline Moreau; Jean Christophe Devedjian; Jérome Kluza; Maud Petrault; Charlotte Laloux; Aurélie Jonneaux; Gilles Ryckewaert; Guillaume Garçon; Nathalie Rouaix; Alain Duhamel; Patrice Jissendi; Kathy Dujardin; Florent Auger; Laura Ravasi; Lucie Hopes; Guillaume Grolez; Wance Firdaus; Bernard Sablonnière; Isabelle Strubi-Vuillaume; Noel Zahr; Alain Destée; Jean-Christophe Corvol; Dominik Pöltl; Marcel Leist; Christian Rose; Luc Defebvre; Philippe Marchetti; Z Ioav Cabantchik; Régis Bordet
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

6.  Inhibition of cellulase-catalyzed lignocellulosic hydrolysis by iron and oxidative metal ions and complexes.

Authors:  Ani Tejirian; Feng Xu
Journal:  Appl Environ Microbiol       Date:  2010-10-01       Impact factor: 4.792

Review 7.  Mitochondrial iron metabolism and its role in neurodegeneration.

Authors:  Maxx P Horowitz; J Timothy Greenamyre
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

8.  Source-dependent intracellular distribution of iron in lens epithelial cells cultured under normoxic and hypoxic conditions.

Authors:  Małgorzata Goralska; Steven Nagar; Lloyd N Fleisher; Philip Mzyk; M Christine McGahan
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-11-19       Impact factor: 4.799

Review 9.  Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities.

Authors:  Neena Singh; Swati Haldar; Ajai K Tripathi; Katharine Horback; Joseph Wong; Deepak Sharma; Amber Beserra; Srinivas Suda; Charumathi Anbalagan; Som Dev; Chinmay K Mukhopadhyay; Ajay Singh
Journal:  Antioxid Redox Signal       Date:  2013-08-15       Impact factor: 8.401

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.